Novel Antibody And Use In Diagnosis And Therapy Of Arthropathies

a technology of arthropathies and antibodies, applied in the field of new antibody and use in diagnosis and therapy of arthropathies, can solve the problems of increasing the risk of serious infections and malignancies, inconsistent effectiveness, and increasing the number of patients that fail anti-tnf therapy
US20160228570A1Inactive Publication Date: 2016-08-11QUEEN MARY UNIV OF LONDON
0 Cites 7 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
QUEEN MARY UNIV OF LONDON
Publication Date
2016-08-11
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (CII) in which the antibody or fragment thereof is conjugated to a pharmaceutically active moiety. The invention also provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (CII) and a detectable label. The invention further provides the use of such compositions in medicine, in particular for the treatment of an arthropathy, and in methods of diagnosis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to a novel antibody and its use in the diagnosis and therapy of inflammatory diseases of the joints such as rheumatoid arthritis (RA) and osteoarthritis (OA).INTRODUCTION

[0002] The final outcome of most rheumatic conditions, the leading cause of disabilities in the western world, is breakdown of articular cartilage. This breakdown is the final outcome of inflammatory events in both rheumatoid arthritis (RA) and osteoarthritis (OA) mediated by either influx of activated leukocytes (RA) or activated chondrocytes (OA). Pro-inflammatory cytokine blockade such as anti-TNFa and IL-1Ra is therefore currently used to treat arthritic conditions, mainly RA. These treatments however, are not consistently effective and the number of patients that fail anti-TNF therapy is increasing. Especially for anti-TNFa treatment there is a risk of serious infections and malignancies. These systemic side effects could be minimised by the development of technologies to targ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More